BetaGlue Therapeutics

medical devices

About

BetaGlue Therapeutics is an Italian clinical-stage life sciences company focused on innovative cancer treatment through its internal radiotherapy platform, YntraDose®. This technology allows for the precise and personalized delivery of radiotherapy directly into solid tumors, enhancing treatment efficacy while minimizing side effects. The company aims to provide cost-effective and easy-to-use radiotherapy solutions for patients with solid tumors. YntraDose® is designed for targeted treatment, particularly for unresectable tumors and post-surgical care, making it a valuable option for interventional radiologists and healthcare providers. BetaGlue Therapeutics operates in the global oncology market, generating revenue through the sale of its proprietary medical devices and pursuing partnerships to expand its reach. With significant funding support, the company is well-positioned to advance its mission of improving cancer care worldwide.

Technologies

Outlook Microsoft Office 365 WordPress.org Apache Gravity Forms Vimeo Google Font API Mobile Friendly AI

Keywords

radiotherapy nuclear medicine oncology medical devices medical equipment manufacturing organ movement compensation biocompatible bioglue organ-specific treatment targeted tumor ablation imaging guidance treatment safety oncology innovation internal radiotherapy d2c medical device efficacy outcomes healthcare technology treatment efficacy treatment accessibility interventional oncology b2b hydrogel matrix loaded with y-90 healthcare targeted cancer therapy organ preservation solid tumor treatment percutaneous radiotherapy single session radiotherapy intratumoral injection local dose escalation

Location

4 Piazzetta Umberto Giordano, Milan, Lombardy, Italy, 20122

Related Companies

Companies in the same industry